Home
NewsNewsFairfax IVI expand donor sperm access through a strategic partnership that enhances availability, integrates donor services into fertility care, and supports diverse patient needs. With personalised guidance, genetic insights, and streamlined logistics, the collaboration aims to reduce barriers and deliver a more accessible, inclusive path to parenthood.
In a significant move for the reproductive medicine industry, Fairfax Cryobank and IVI RMA North America have officially announced a strategic partnership designed to Fairfax IVI expand donor sperm access. This collaboration seeks to provide individuals and couples with high-quality donor sperm, significant savings, and premium support services as they pursue their family-building goals.
Through this new alliance, IVI RMA North America patients will gain direct access to Fairfax Cryobank’s extensive nationwide network of diverse donors. Beyond increasing the availability of donor sperm, the partnership introduces various programmes aimed at enhancing financial accessibility and overall value for patients. Key benefits include personalised guidance, genetic compatibility insights, and flexible programme options tailored to the unique needs of each family.
To ensure a seamless experience, Fairfax Cryobank will manage the shipping and secure storage of samples while providing dedicated support throughout the process. The integration of these services into IVI RMA’s clinical framework is intended to reduce the logistical and emotional complexities often associated with fertility treatments.
Dr. Thomas Molinaro, Chief Medical Officer of IVI RMA North America, highlighted the importance of this collaboration for patient care: “This partnership with Fairfax Cryobank is an important advancement in our mission to expand access to high-quality, patient-centred fertility care to all Americans. By combining IVI RMA's clinical expertise with Fairfax Cryobank's high-quality diverse donor sperm and value-added services, we are reducing the financial and emotional barriers to reproductive treatment and empowering more individuals and families to pursue parenthood with greater confidence and clarity.”
The partnership will see Fairfax Cryobank’s donor selection process fully integrated into the personalised fertility treatment plans at IVI RMA’s 27 North American laboratories. This streamlined approach includes coordinated lab services and genetic counselling, allowing patients to make more informed clinical decisions. Furthermore, both organisations have reaffirmed their commitment to inclusive services, supporting LGBTQ+ families, single moms by choice, and any individuals requiring donor sperm to build their families. Dr. Harvey Stern, MD, PhD, Medical Director of Fairfax Cryobank, expressed his pride in the joint effort:
“We are proud to partner with IVI RMA North America to deliver a seamless patient-centred experience for those building their families. By combining our extensive donor network, secure storage, and personalised guidance with IVI RMA's clinical leadership and advanced IVF laboratories, we are ensuring patients receive trusted support at every step of their journey.”
Fairfax Cryobank, established in 1986, is renowned for its comprehensive donor screening and testing procedures, operating seven locations across the United States to serve recipients globally. IVI RMA North America, which includes Reproductive Medicine Associates, Boston IVF, and TRIO, has facilitated the birth of over 220,000 babies to date. As part of IVI RMA Global, the network remains a leader in evidence-based fertility solutions, employing over 6,000 people across 15 countries.
apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.
Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.
TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
UNC Fertility has announced its plans for Collaboration with IVI RMA North America to bring best clinical and operational best practices across the region, expanding access to cutting-edge fertility treatments and research.
Alife Health has secured FDA clearance for Embryo Predict, its AI-powered embryo assessment tool for IVF. Backed by a 440-patient, seven-center randomized clinical trial, the platform delivers data-driven embryo selection insights to embryologists across the U.S., Europe, and the U.K., addressing longstanding variability in clinical decision-making.
